Elevated Fasting Blood Glucose Levels Are Associated With Lower Cognitive Function, With a Threshold in Non-Diabetic Individuals: A Population-Based Study. by LIU Ziyi et al.
Elevated Fasting Blood Glucose Levels Are
Associated With Lower Cognitive Function, With
a Threshold in Non-Diabetic Individuals: A
Population-Based Study.
著者 LIU Ziyi, ZAID Maryam, HISAMATSU Takashi,
Tanaka-Mizuno Sachiko, FUJIYOSHI Akira,
MIYAGAWA Naoko, ITO Takahiro, KADOTA Aya,
TOOYAMA Ikuo, MIURA Katsuyuki, UESHIMA
Hirotsugu
journal or
publication title
Journal of epidemiology
volume 30
number 3
page range 121-127
year 2020-03-05
URL http://hdl.handle.net/10422/00012639
doi: 10.2188/jea.JE20180193(https://doi.org/10.2188/jea.JE20180193)
(C) 2019 Ziyi Liu et al. 
This is an open access article distributed under the terms of Creative 
Commons Attribution License, which permits　unrestricted use,　distribution, and reproduction in any
medium, provided the original author and source are credited.
Original Article J Epidemiol 2020;30(3):121-127
Elevated Fasting Blood Glucose Levels Are Associated With Lower
Cognitive Function, With a Threshold in Non-Diabetic Individuals:
A Population-Based Study
Ziyi Liu1,2, Maryam Zaid3, Takashi Hisamatsu3,4, Sachiko Tanaka5, Akira Fujiyoshi2, Naoko Miyagawa2,
Takahiro Ito2, Aya Kadota2,3, Ikuo Tooyama1, Katsuyuki Miura2,3, and Hirotsugu Ueshima2,3,
for the SESSA Research Group
1Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga, Japan
2Department of Public Health, Shiga University of Medical Science, Shiga, Japan
3Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Shiga, Japan
4Department of Environmental Medicine and Public Health, Faculty of Medicine, Shimane University, Shimane, Japan
5Department of Medical Statistics, Shiga University of Medical Science, Shiga, Japan
Received October 4, 2018; accepted February 15, 2019; released online May 25, 2019
ABSTRACT
Background: Cognitive dysfunction has been recognized as a diabetes-related complication. Whether hyperglycemia or elevated
fasting glucose are associated with cognitive decline remains controversial. We aimed to investigate the relationship between
fasting glucose levels and cognitive function in diabetic and non-diabetic individuals.
Methods: Participants were Japanese diabetic (n = 191) and non-diabetic (n = 616) men, aged 46–81 years, from 2010–2014.
Blood samples were taken after a 12 h fast. The Cognitive Ability Screening Instrument (CASI), with a maximum score of 100,
was used for cognitive assessment. Cognitive domains of CASI were also investigated. Fractional logit regression with covariate
adjustment for potential confounders was used to model cross-sectional relationships between fasting blood glucose and CASI
score.
Results: For diabetic individuals, CASI score was 0.38 (95% confidence interval: 0.66–0.12) lower per 1mmol=L higher fasting
glucose level. Short-term memory domain also exhibited an inverse association. For non-diabetic individuals, a reverse U-
shaped relationship was observed between fasting glucose and cognitive function, identifying a threshold for highest cognitive
performance of 91.8 CASI score at 3.97–6.20mmol=L (71.5–111.6mg=dL) fasting glucose. Language ability domain displayed
a similar relationship with fasting glucose.
Conclusions: Elevated fasting glucose levels in diabetic men were associated with lower cognitive function, in which short-term
memory was the main associated domain. Interestingly, in non-diabetic men, we identified a threshold for the inverse
relationship of elevated fasting glucose with cognitive function. Contrastingly to diabetic men, language ability was the main
associated cognitive domain among non-diabetic men.
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INTRODUCTION
Global prevalence of diabetes is projected to increase, and by
2030 around 366 million people worldwide are expected to be
affected.1 Individuals with diabetes mellitus have increased risk
of cognitive dysfunction.2,3 Studies have reported that diabetic
patients have up to a 2.5-fold greater risk of dementia compared
to non-diabetic individuals.4,5 As a diabetes-related complication,
dementia has become a serious burden to Japanese society,
healthcare, and economy.6
Diabetes is a multifactorial and complex disease that is
associated with other metabolic and health complications.7–9
However, its underlying conditions, such as hyperglycemia and
insulin resistance, are considered to be the link between diabetes
and cognitive decline.10 Studies suggest that hyperglycemia-
related increased oxidative stress and accumulation of advanced
glycation end-products (AGEs) can lead to vascular and
neurovascular damage.11,12 However, there are some studies that
report little to no association between hyperglycemia and
cognitive dysfunction in type II diabetes.13
There are fewer studies on fasting glucose levels and cognitive
function in non-diabetic individuals.14 Moreover, conflicting re-
sults have been reported on whether elevated fasting glucose in non-
diabetic individuals are associated with cognitive impairment.15–18
This has led to the speculation about a threshold for effects of
glucose on cognitive function in non-diabetic individuals.15
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We aimed to analyze the associations of fasting blood glucose
with cognitive function and cognitive domains in non-diabetic
and diabetic Japanese men.
METHODS
Study participants
The Shiga Epidemiological Study of Subclinical Atherosclerosis
(SESSA) is a population-based study which recruited 40- to
79-year-old men, randomly selected in 2006–2008 (baseline),
from the general population in Kusatsu City, Shiga, Japan
(participation rate of 46%).19–21 Although SESSA is an
observational cohort study with follow-up in 2010–2014, our
present analysis only involves data from the follow-up because
CASI score was not measured at baseline. A total of 853 men
participated in the follow-up, a participation rate of 78% (see
eFigure 1 for selection flow).
A questionnaire was completed by all participants. Data on
years of education, medical history, use of medication (such as
hypertension, hyperlipidemia, and diabetes medication), and
other lifestyle characteristics were collected.
Each participant had undergone a physical examination
involving measurements of height, weight, blood pressure, and
other various physical attributes. Blood pressure was measured
after 5 minutes of rest in a seated position using an automated
sphygmomanometer (BP-8800; Omron Colin, Tokyo, Japan). An
average of two blood pressure measurements was used.
Participants with a systolic blood pressure (SBP) of ≥140
mmHg, a diastolic blood pressure (DBP) of ≥90mmHg, or the
use of antihypertensive medication were characterized as having
hypertension. Body mass index (BMI) was defined as weight
divided by height squared (kg=m2). Current smokers were defined
as individuals who smoked tobacco within the last 30 days.
Current drinkers were defined as individuals who answered “yes”
to the question “do you currently drink alcohol?”.
After excluding participants with self-reported Parkinson’s
disease (n = 4) and with missing information on fasting blood
glucose values or CASI score (n = 43), a total of 807 men aged
46–81 years remained in the current analysis. All participants
provided written and informed consent. This study complies
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) and was approved by the Institutional
Review Board of Shiga University of Medical Science, Otsu,
Japan.
Blood samples, glucose, and diabetes
Fasting blood samples were taken from participants after a 12 hour
fast. Standard lipids were measured using enzymatic techniques.
Lipid measurements were standardized according to the guidelines
from the Center for Disease Control and Prevention=Cholesterol
Reference Method Laboratory Network.22 Sodium fluoride-treated
plasma was used to measure fasting blood glucose by hexokinase=
glucose-6-phosphate dehydrogenase enzymatic assay. Glycated
hemoglobin A1c (HbA1c) was measured by latex agglutination
assay according to National Glycohemoglobin Standardization
Program (NGSP) or Japan Diabetes Society (JDS) protocol. The
number of participants who had HbA1c measured by NGSP or
JDS was 194 and 743, respectively. JDS values were converted
to NGSP values using the following equation23: NGSP (%) =
1.02 × JDS value (%) + 0.25. International Federation of Clinical
Chemistry (IFCC) values for HbA1c can be calculated from NGSP
values using the following equation: IFCC (mmol=mol) =
10.93 × NGSP (%) − 23.50. Diabetes was defined as taking
diabetes medication, blood glucose to ≥6.99mmol=L (≥126
mg=dL) or HbA1c ≥6.5% (NGSP).
Cognitive Ability Screening Instrument
CASI was used to assess cognitive ability. CASI is a 15–20
minute cognitive assessment that was developed for cross-cultural
use, which has also been found to closely estimate scores from
other cognitive tests, such as Mini-Mental State Examination
(MMSE).24 A trained technician used the Japanese version of
CASI (CASI J-1.0) to assess cognitive function. In CASI, a total
of nine cognitive domains were assessed (maximum points):
attention (8 points), concentration=mental manipulation (10
points), orientation (18 points), short-term memory (12 points),
long-term memory (10 points), language (10 points), visual
construction (10 points), list-generating fluency (10 points), and
abstraction=judgement (12 points). The scores in all domains
were added to provide a total CASI score with a range of 0 to
100, with higher scores indicating better cognitive function.24
Statistical analysis
All analyses were performed on non-diabetic and diabetic
participants separately. Participant demographics were described
according to diabetes status. Differences between non-diabetic
and diabetic groups were assessed with student’s t-test (means)
for continuous variables and χ2 test (proportions) for categorical
variables.
Non-diabetic and diabetic participants were separated into
groups according to deciles of fasting blood glucose. Analysis of
covariance was used to calculate mean total CASI score, adjusted
for age, total years of education, and (for diabetic only) use of
diabetes medication for all decile groups.
Fractional logit regression was used to model the relationship
between CASI and fasting blood glucose as total CASI score has
minimum and maximum limits (0 and 100). Thus, to ensure
predicted values fall between these limits, CASI was modeled
as a proportion by the total maximum score (CASI=100) in the
fractional logit model. Similarly, CASI domain scores were
divided by their allotted maximum points (eg, short-term memory
was divided by 8). Both linear and quadratic relationships
between glucose and CASI were explored in non-diabetic and
diabetic individuals. The linear relationship between CASI and
glucose was modeled (in its simplest form) as: CASI=100 =
1=(1 + e−(ax+b)), where x is glucose. For quadratic analyses, a
similar equation was used, but instead with the negative exponent
of e being ax2 + bx + c. Estimated glucose level at peak CASI
score was obtained from the vertex equation (−b=2a). Bootstrap
method, with 1,000 samples of data generated randomly from
original data (with replacement), was used to identify 95%
confidence limits of the glucose estimate at peak CASI score
using 2.5 and 97.5 percentiles of estimated peak glucose.
Regression models were adjusted for the following covariates:
(model 1) age and total years of education, (model 2) Model
1 + body mass index, systolic blood pressure, hypertension
medication (yes=no), lipid medication (yes=no), and smoking
status (yes=no). In diabetic individuals, all models were further
adjusted for diabetic medication (yes=no). No interactions were
evident for age as a continuous variable or as a categorical
variable (<65 and ≥65 years old) with CASI and fasting blood
glucose in either non-diabetic or diabetic individuals.
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All analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC, USA) and two-tailed P-values were
reported.
RESULTS
Of the total 807 Japanese male participants, 616 were non-diabetic
and 191 were diabetic. Mean age of non-diabetic and diabetic
participants was 67.6 and 69.8 years, respectively. Diabetic
participants were older, had higher SBP and BMI, and had lower
levels of total and HDL cholesterol. They were more likely to be
current smokers and to take hypertension and lipid medication
than non-diabetic participants (Table 1). Compared to non-
diabetic participants, diabetic participants had a lower total CASI
score and generally lower CASI domain scores, especially for
concentration and short-term memory (Table 2). Non-diabetic
participants had a mean fasting blood glucose level of 5.2mmol=L
and a range of 3.7–6.9mmol=L. Diabetic participants had a mean
glucose value of 7.1mmol=L and a range of 2.5–14.9mmol=L.
Non-diabetic individuals
According to decile analysis, mean CASI scores adjusted for age
and total years of education appear to have a curved relationship
with fasting blood glucose (Figure 1). Nevertheless, both linear
and quadratic relationships were investigated between glucose
and CASI. No linear relationship was identified in non-diabetic
individuals between glucose and CASI, even after adjustment for
potential confounders and effect modifiers (data not shown).
However, a reverse U-shaped relationship (ie, having a negative
coefficient for the quadratic term) was found (Table 3). The
vertex (ie, peak CASI score) of the quadratic function was
identified as having an estimated 95% confidence range for
glucose of 4.42 to 6.20mmol=L (79.6 to 111.6mg=dL) and
highest CASI score of 91.8 with adjustments for age and total
years of education (model 1). Further adjustment for BMI, SBP,
hypertension medication, lipid medication, and smoking status
(model 2) resulted in a similar range of 3.97 to 6.20mmol=L
(71.5 to 111.6mg=dL) and highest CASI score of 91.8. With
regard to CASI domains, only language ability domain had a
reverse U-shaped relationship with glucose (Table 3), whereas
other CASI domains did not (eTable 1).
Diabetic individuals
Mean CASI scores adjusted for age, total years of education, and
diabetic medication appear to have an inverse linear relationship
with deciles of fasting blood glucose (Figure 1). No quadratic
relationship was evident between glucose and CASI in diabetic
individuals (data not shown). However, we observed a significant
inverse linear relationship between glucose and CASI (Table 4),
with adjustments made for age, total years of education, and
diabetes medication (model 1). This relationship was maintained
after further adjustments for BMI, SBP, hypertension medica-
tion, lipid medication, and smoking status (model 2). An inverse
linear relationship of glucose was only evident with short-term
memory CASI domain (Table 4) and not with other domains
(eTable 2).
Table 1. Characteristics of men aged 46–81 years according to
diabetes status in 2010–2014, Shiga, Japan (n = 807)
Characteristic
Non-Diabetic
(n = 616)
Diabetic
(n = 191)
P-value
Age, years 67.6 (8.4) 69.8 (6.9) <0.001
Years of education 12.8 (2.4) 12.7 (2.4) 0.428
SBP, mmHg 131 (17) 134 (16) 0.039
Body mass index, kg=m2 23.1 (2.8) 24.2 (3.4) <0.001
Total cholesterol, mmol=L 5.2 (0.9) 5.1 (0.9) 0.033
HDL-cholesterol, mmol=L 1.6 (0.4) 1.4 (0.4) <0.001
Smoking amount, cig=day 3.0 (7.1) 4.5 (9.2) 0.036
Current smoker, % 19.7 26.2 0.055
Current drinker, % 80.5 75.4 0.129
Hypertension medication, % 35.0 59.2 <0.001
Diabetes medication, % 0.0 69.6 <0.001
Lipid medication, % 16.9 40.8 <0.001
HDL, high-density lipoprotein; SBP, systolic blood pressure.
Data are presented as mean (standard deviation), or as percentages, as
indicated.
P-value for the difference between non-diabetic and diabetic group was
derived from student’s t-test for comparison of means or χ2 test for
comparison of percentages.
Table 2. Fasting blood glucose, HbA1c, and total and domain CASI scores in non-diabetic and diabetic men
Measure
Non-Diabetic (n = 616) Diabetic (n = 191)
P-value
Mean (SD) Median (IQR) Range Mean (SD) Median (IQR) Range
Glucose, mmol=L 5.2 (0.5) 5.2 (4.9–5.6) 3.7–6.9 7.1 (1.8) 7.0 (6.1–7.6) 2.5–14.9 <0.001
HbA1c, %a 5.6 (0.4) 5.6 (5.4–5.9) 4.3–6.4 7.0 (1.0) 6.8 (6.5–7.4) 5.0–12.9 <0.001
CASI score (=100 points) 91.1 (5.7) 92 (88–95) 66–100 90.0 (6.2) 91 (87–94) 63–100 0.024
Attention (=8 points) 7.0 (1.0) 7 (6–8) 3–8 6.8 (1.0) 7 (6–8) 5–8 0.145
Concentration (=10 points) 9.0 (1.4) 10 (8–10) 1–10 8.7 (1.7) 10 (8–10) 1–10 0.017
Orientation (=18 points) 17.7 (0.9) 18 (18–18) 7–18 17.7 (1.0) 18 (18–18) 9–18 0.654
Short-term memory (=12 points) 9.5 (2.1) 10 (8–11) 1–12 9.1 (2.2) 10 (8–11) 3–12 0.033
Long-term memory (=10 points) 10.0 (0.3) 10 (10–10) 8–10 9.9 (0.4) 10 (10–10) 7–10 0.441
Language (=10 points) 9.8 (0.5) 10 (10–10) 7–10 9.8 (0.7) 10 (10–10) 5–10 0.232
Visual construction (=10 points) 9.8 (0.8) 10 (10–10) 0–10 9.8 (0.4) 10 (10–10) 8–10 0.594
List-generating fluency (=10 points) 8.8 (1.6) 10 (8–10) 0–10 8.8 (1.6) 9 (8–10) 2–10 0.752
Abstraction (=12 points) 9.5 (1.8) 10 (9–11) 3–12 9.4 (1.8) 10 (8–11) 4–12 0.392
CASI, Cognitive Ability Screening Instrument; HbA1c, glycated hemoglobin A1c; IQR, interquartile range; SD, standard deviation.
The maximum points allotted for CASI and its domains are indicated (eg =10 points).
P-value was derived from student’s t-test and is for the difference between non-diabetic and diabetic groups.
For conversion of glucose from mmol=L to mg=dL, multiply by 18.
aNGSP HbA1c levels. To convert to IFCC HbA1c values: IFCC (mmol=mol) = 10.93 × NGSP (%) − 23.50.
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DISCUSSION
Summary
In both non-diabetic and diabetic men, we identified significant
relationships of fasting blood glucose with total CASI score. In
non-diabetic men, this was a reverse U-shaped relationship,
suggesting a threshold at a glucose range of 3.97 to 6.20mmol=L
and language ability was a significant domain in this relationship.
Whereas in diabetic men, an inverse linear relationship between
fasting glucose and CASI was observed and short-term memory
was a significant domain.
Non-diabetic individuals
In non-diabetic individuals, we identified a range of glucose that
is associated with highest CASI score. The reverse U-shaped
relationship between glucose and CASI in non-diabetic
individuals involved a peak CASI score within a 95% confidence
glucose range of 4.42 to 6.20mmol=L (79.6mg=dL to 111.6
mg=dL) in a model adjusted for age and total years of educa-
tion (model 1). With further adjustments for other important
covariates (model 2), this range broadened at the lower extremity
to become 3.97 to 6.20mmol=L. The higher extreme glucose
value of the range is very close to the cut-off for impaired fasting
glucose (≥6.1mmol=L or 110mg=dL) recommended by WHO.25
Our study suggests presence of a threshold for the relationship
between glucose and cognitive function and that impaired fasting
glucose may be associated with cognitive impairment. There were
limited number of participants in our study with glucose values
near the lower extremity of the range. Only two participants in
our study had glucose levels of less than 3.97mmol=L. The lower
extreme value of the range may not be conclusive and this was
evident as this value was susceptible to change with further
covariate adjustment, unlike the higher extreme value. Moreover,
as participants were given the CASI test at a pre-prandial state,
lack of food intake may have affected participants’ test
performance,26 especially for those with low fasting blood
glucose levels. Thus, although our study shows a reverse U-
shaped relationship between cognitive function and fasting blood
glucose, we cannot conclude that individuals with lower fasting
blood glucose have lower cognitive ability.
Figure 1. Adjusted mean total CASI scores by deciles
of glucose in A) non-diabetic and B) diabetic
men. Data presented are means with standard
errors (error bars). Means were adjusted for age,
total years of education, and (for diabetics only)
diabetic medication. Mean CASI scores between
glucose deciles were calculated and compared
using analysis of covariance. CASI, Cognitive
Ability Screening Instrument; REF, reference
group. *P = 0.05, **P < 0.05
Table 3. Estimated fasting blood glucose range associated with
the highest total and domain CASI scores from the
reverse U-shaped relationship in non-diabetic men
Score
Highest score
estimate
Glucose
(mmol=L)
P-value
Model 1 Total CASI 91.8 4.42–6.20 0.042
Language 9.9 4.53–5.79 0.007
Model 2 Total CASI 91.8 3.97–6.20 0.044
Language 9.9 4.66–5.91 0.007
CASI, Cognitive Ability Screening Instrument.
Model 1 was adjusted for age and total years of education.
Model 2 was adjusted for age, total years of education, body mass index,
systolic blood pressure, hypertension medication (yes=no), lipid medication
(yes=no), and smoking status (yes=no).
P-value of quadratic coefficient (glucose+glucose), signifying a significant
quadratic or U-shaped relationship, is displayed.
Estimated glucose range of peak CASI score was derived from the 95%
confidence glucose values of the vertex of the quadratic function obtained
from bootstrap sampling method (1000). Other CASI domains had non-
significant relationships with glucose (see eTable 1).
Table 4. Estimated difference in total and domain CASI scores
per 1mmol/L higher fasting blood glucose from the
linear relationship in diabetic men
Score ΔCASI 95% CI P-value
Model 1 Total CASI −0.41 −0.70 to −0.17 0.038
Short-term memory −0.17 −0.24 to −0.05 0.022
Model 2 Total CASI −0.38 −0.66 to −0.12 0.050
Short-term memory −0.16 −0.23 to −0.04 0.034
ΔCASI, difference in Cognitive Ability Screening Instrument; CI, con-
fidence interval.
Model 1 was adjusted for age, total years of education and diabetic
medication (yes=no).
Model 2 was adjusted for age, total years of education, diabetic medication
(yes=no), body mass index, systolic blood pressure, hypertension medication
(yes=no), lipid medication (yes=no), and smoking status (yes=no).
Other CASI domains had non-significant relationships with glucose (see
eTable 2).
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There are limited studies on the relationship of blood glucose
with cognitive function in non-diabetic individuals. However, in a
community-based cohort,27 individuals with borderline diabetes
had a higher 5-year hazard ratio of dementia and Alzheimer’s
disease compared to those without borderline diabetes. Crane
et al have also reported that in non-diabetic individuals, those
with higher calculated average glucose levels in the preceding
5 years were at increased risk of dementia.14 The findings in these
two studies suggest that even in individuals without diabetes,
long-term exposure to high glucose levels leads to cognitive
decline. In contrast, a study by Euser et al15 found no association
between baseline fasting blood glucose levels and changes in
cognitive function in non-diabetic individuals. However, this
study has only assessed linear associations of baseline fasting
glucose with cognitive test score and its changes over time in
non-diabetic individuals. Interestingly, cross-sectional analysis of
baseline data involving graphs depicting mean cognitive test
score among quintiles of fasting glucose levels suggested a
reverse U-shaped association, similar to our findings.
Diabetic individuals
Although most studies on the relationship between glycemia
and cognitive function have focused on diabetic individuals,
inconsistent results were reported.28 Many studies, including a
cohort study from Japan, have reported that people with diabetes
have a greater risk of cognitive decline, dementia and
Alzheimer’s disease.8,28–31 However, studies on the spectrum of
glucose levels with cognitive function in diabetic individuals are
rare. Crane et al has found that higher calculated average glucose
levels in diabetic individuals were related to an increased risk
of dementia.14 With regard to hypoglycemia, diabetic patients
with hypoglycemia-associated hospitalizations were found to be
at two-fold increased risk of developing dementia.32 Yet, we
could not investigate such a relationship with cognitive function,
as only four diabetic individuals had fasting blood glucose levels
of <3.9mmol=L (<70mg=dL). However, we found that the first
blood glucose decile group had a discernable lower mean CASI
score compared to the adjacent groups (Figure 1B).
CASI and its domains
CASI is a cross-cultural cognitive test that provides a quantitative
assessment of various components of cognitive function and was
designed to screen for dementia, monitor disease progression
and to provide profiles of cognitive impairment.24 Importantly,
dementia patients were found to have lower mean CASI
compared to control subjects.24 Short-term memory was identified
as one of the most sensitive CASI domains for distinguishing
dementia patients from controls.24 In our results, glucose had an
inverse relationship with short-term memory in diabetic indivi-
duals. Also, short-term memory was one of the two domains in
which participants with diabetes obtained significantly lower
scores than participants without diabetes. In participants without
diabetes, rather than memory, language ability had a reverse U-
shaped relationship with fasting blood glucose. It is not known
whether low scores in memory or language in cognitive tests are
precursors of true dementia or whether they represent other
processes. Also, the early stages of different types of dementia
can be substantially different from one another. Short-term
memory is predominantly a hippocampal function,33 while
language ability is a function of the temporal cortex and the
inferior frontal cortex.34 However, the brain functions as an
integrated network and thus labelling areas of the brain as focal
areas of cognitive test components should be done so cautiously.
Regardless, the different domains of CASI that are associated
with high fasting blood glucose in non-diabetic and diabetic
individuals suggests that blood glucose may affect cognitive
function in these individuals using different pathways, possibly
producing different long-term outcomes.
Strengths and limitations
There are several limitations to our study. First, our study is
cross-sectional and only provides a snapshot of the relationship
between glucose and CASI. Also, we only present data on men
and, thus, it is unclear whether these findings can be replicated in
women. Moreover, residual confounding by other factors not
considered (such as history of stroke, exercise, sleep apnea, and
depression) cannot be ruled out.
Our study has some important strengths. First, we assessed a
continuous variable of cognitive function over a spectrum of
fasting blood glucose levels in both non-diabetic and diabetic
individuals. Other studies have used calculated average glucose
levels14 or have not done so in both non-diabetic and diabetic
individuals.15 Second, we were able to identify a relationship with
glucose prior to onset of dementia or Alzheimer’s disease in
generally healthy individuals. Third, we identified different types
of relationships of fasting blood glucose with cognitive function
by diabetes status and found a threshold of fasting blood glucose
for highest cognitive performance in individuals without diabetes.
Finally, we identified specific domains of cognitive function that
may be related to cognitive impairment in non-diabetic and
diabetic individuals.
Conclusion
We have identified relationships of fasting blood glucose and
cognitive function in non-diabetic and diabetic men. A reverse
U-shaped relationship was observed in non-diabetic men and we
identified the threshold of fasting blood glucose for highest
cognitive performance at a cut-off of <6.2mmol=L. Language
ability score also showed a similar trend. An inverse linear
relationship was found in diabetic men, with short-term memory
being a significant domain. For greater insight into the plausible
causal relationship between blood glucose and cognitive ability,
longitudinal observational studies are needed, especially in non-
diabetic individuals.
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